(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 22.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.1%.
Voyager Therapeutics's revenue in 2026 is $40,374,000.On average, 14 Wall Street analysts forecast VYGR's revenue for 2026 to be $3,228,498,144, with the lowest VYGR revenue forecast at $467,259,100, and the highest VYGR revenue forecast at $7,773,546,481. On average, 14 Wall Street analysts forecast VYGR's revenue for 2027 to be $3,480,841,898, with the lowest VYGR revenue forecast at $467,259,100, and the highest VYGR revenue forecast at $7,693,087,325.
In 2028, VYGR is forecast to generate $4,584,681,922 in revenue, with the lowest revenue forecast at $1,168,147,750 and the highest revenue forecast at $13,893,806,300.